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The autoimmune form of atypical hemolytic uremic
syndrome (HUS) is characterized by circulating
autoantibodies against the complement regulator factor H,
and is often associated with deficiency of the factor H-related
proteins CFHR1 and CFHR3. Here we studied whether
anti-factor H autoantibodies crossreact with CFHR1, and
determined functional consequences of this. In ELISA, anti-
factor H immunoglobulin G (IgG) autoantibodies from 24
atypical HUS patients bound to the short consensus repeat
20 domain of factor H, 21 antibodies also recognized CFHR1,
but none CFHR3. Three patients also had anti-factor H IgA
autoantibodies crossreacting with CFHR1. Analysis of the IgG
fractions in CFHR1-deficient patients found that CFHR1–IgG
complexes were formed during plasma exchange treatment,
indicating that autoantibodies recognize CFHR1 in vivo.
Recombinant CFHR1 prevented hemolysis of sheep
erythrocytes caused by patient plasma containing anti-factor
H IgG, but it did not inhibit red cell lysis caused by a factor H
mutation (W1183 L) in the short consensus repeat 20 domain.
Thus, exogenous CFHR1 provided during plasma exchange
therapy may neutralize anti-factor H autoantibodies and help
in the treatment of autoimmune atypical HUS.
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Atypical hemolytic uremic syndrome (aHUS) is a severe
kidney disease characterized by hemolytic anemia, thrombo-
cytopenia, and acute renal failure, and is associated with
dysregulation of complement activation.1 aHUS-associated
mutations and polymorphisms in complement genes,2 and
genomic rearrangements involving the factor H (CFH) and
factor H-related (CFHR) genes,3,4 have been identified as
disease predisposing factors. In addition, an autoimmune
form of aHUS is caused by autoantibodies against the
complement regulator factor H (fH).5
fH belongs to a protein family that also includes factor
H-like protein 1 (alternative splicing product of the CFH
gene) and five factor H-related (CFHR) proteins.6 These
proteins are composed of four to nine short consensus repeat
(SCR) domains, and share various degrees of sequence
identity with each other and with fH. In particular, the five
CFHR proteins have domains homologous to the C-terminal
domains SCR19-20 of fH, which are responsible for directing
the complement regulatory activity of fH to cell and tissue
surfaces.7–9 Autoantibodies of most aHUS patients recognize
the C terminus of fH, and inhibit the protective activity of
fH on cells against complement attack.10–12
Anti-fH immunoglobulin G (IgG) has been identified in
approximately 5–11% of aHUS patients in four cohorts.5,10–13
The majority of the patients present with deficiency of
CFHR1 and CFHR3, resulting from a homozygous deletion
of the genomic region including both genes.11–14 However,
anti-fH IgG has also been described in patients having two
copies of CFHR1 and CFHR3,12,13 and in patients with other
genetic alterations, including one patient with homozygous
CFHR1/CFHR4A deletion,13 three patients with combined
CFHR1/CFHR3 and CFHR1/CFHR4A deletions,12,13 and one
patient with combined CFHR1/CFHR3 deletion and a
missense mutation in CFHR1.13 Furthermore, autoantibodies
may occur together with mutations in CFH, CFI, CD46, or
C3.12 Thus, anti-fH autoantibodies are not associated with a
single genetic defect, but in most cases they occur together
with a complete deficiency of CFHR1. Here, we have analyzed
whether anti-fH autoantibodies crossreact with CFHR1 and
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other CFHR proteins, and studied the functional relevance
of antibody crossreactivity.
RESULTS
Anti-fH autoantibodies crossreact with CFHR1
The C-terminal domains of the CFHR1, CFHR3, and
CFHR4A proteins, which are affected by genomic rearrange-
ments in most aHUS patients with anti-fH autoantibodies,
display 64–100% amino-acid sequence identity with SCR19
of fH, and 37–97% identity with SCR20 (Figure 1a). We have,
therefore, tested whether anti-fH autoantibodies crossreact
with these CFHR proteins. Samples from 24 patients with
anti-fH IgG from two cohorts (German and Spanish) were
analyzed; clinical data available have been reported pre-
viously.11,13,15 All anti-fH IgG bound to SCR19–20 of fH
(data not shown).10,11,15 The majority (21 out of 24) of the
anti-fH IgG analyzed bound to recombinant CFHR1 in
enzyme-linked immunosorbent assay, whereas no significant
binding to CFHR3 and CFHR4A was observed (Figure 1b
and Table 1). Most autoantibodies showed a similar binding
intensity to CFHR1 and to fH (e.g., patients P5, P6,
and P20), but some had a weaker binding to CFHR1
(e.g., patients P7, P8, and P15). Autoantibodies from three
patients did not show significant CFHR1 binding in the assay
(e.g., patient P17); interestingly, two of these patients were
not CFHR1 deficient (Table 1). Binding of two autoanti-
bodies to plasma-derived fH and CFHR1 was also analyzed
by western blot, using patient IgG as the primary antibody.
Both native fH and the two CFHR1 isoforms were recognized
by the patients’ IgG, but not by IgG derived from a healthy
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Figure 1 | aHUS-associated anti-fH autoantibodies crossreact with CFHR1. (a) Alignment of the factor H-related proteins CFHR1, CFHR3,
and CFHR4A with factor H (fH) based on amino-acid sequence similarity. The individual SCR domains of the CFHR proteins are vertically aligned
to the most similar domains of fH. The percentage of amino acid identity between the C-terminal domains of CFHR proteins and homologous
domains in fH is shown. Binding sites of two anti-fH monoclonal antibodies used in this study (OX24 and C18) are also shown. (b) The binding
of 24 anti-fH autoantibodies to recombinant human CFHR proteins was analyzed by enzyme-linked immunosorbent assay. Eight representative
cases are shown to illustrate differential binding to CFHR1 and lack of binding to CFHR3 and CFHR4A. (c) Western blots of purified fH, and of a
plasma preparation containing fH and CFHR proteins. Rabbit polyclonal anti-fH antibody (rb), IgG from patient H154 (H154), IgG from patient
H177 (H177), or IgG from a control individual (C) were used as primary antibodies. Plasma-derived fH and the two CFHR1 isoforms (a and b)
were recognized by IgG from the two patients, but not by the control’s IgG. (d) The mAb C18, which recognizes SCR20 of fH,9 inhibits
autoantibody binding to fH,10 and to CFHR1, as shown here for three representative cases. aHUS, atypical hemolytic uremic syndrome;
BSA, bovine serum albumin; CFHR, complement factor H-related protein; IgG, immunoglobulin G; mAb, monoclonal antibody.
Table 1 | CFHR1/CFHR3 phenotype and autoantibody
crossreactivity with CFHR1
Phenotype (no. of patients)
CFHR1
reactivity
Weak/no
CFHR1 reactivity
CFHR1/CFHR3 (19) 18 1
CFHR1+/CFHR3+ (3) 1 2
CFHR1/CFHR3+ (2)a 2 0
Abbreviations: CFHR, complement factor H-related protein; MLPA, multiplex
ligation-dependent probe amplification.
The 20 German patients were analyzed by western blot for the presence of CFHR1
and CFHR3,3 while the 4 Spanish patients were analyzed by western blot and by
MLPA.13
aOne of the two patients had a homozygous CFHR1/CFHR4A deficiency, determined
by MLPA.13
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individual (Figure 1c). Recognition of plasma-derived
CFHR3 and CFHR4A by the patients’ IgG was not observed.
SCR5 of CFHR1 is almost identical to SCR20 of fH, and
the previously described monoclonal antibody (mAb) C18
recognizes both domains9 and blocks binding of native fH
and CFHR1 to immobilized C3b and to endothelial cells
(Supplementary Figure S1 online). Because mAb C18 has
been reported to inhibit autoantibody binding to fH,10 we
tested its effect on CFHR1 crossreactivity. Complete inhibi-
tion of autoantibody binding to CFHR1 was achieved by
mAb C18 in all samples analyzed, indicating that there were
no additional autoantibodies reacting with the N-terminal
SCR1-2 domains of CFHR1 in these samples (Figure 1d).
In addition, for the first time, in three of the CFHR1/
CFHR3-deficient patients IgA autoantibodies were identified,
which also bound to SCR20 of fH and crossreacted with
CFHR1 (Supplementary Figure S2 online).
CFHR1/autoantibody complexes are formed in vivo
To study whether anti-fH autoantibodies bind to CFHR1 in
plasma, IgG fractions available from four autoantibody-
positive patients were analyzed by western blot. As shown in
Figure 2, fH was present in the IgG fractions of all four aHUS
patients, demonstrating the existence of circulating fH/IgG
complexes. The IgG fractions from patients P6 and P20 also
contained the two CFHR1 isoforms (CFHR1a and CFHR1b).
Patient P6 was not deficient in CFHR1, and patient P20
was CFHR1-deficient but received plasma treatment. Thus,
CFHR1/IgG complexes were formed in CFHR1-containing
plasma of the two patients. fH- or CFHR1-immune
complexes were not detected in healthy individuals (Figure 2).
To further address the in vivo generation of CFHR1/
autoantibody complexes, we analyzed serum samples from
two patients with autoantibodies and homozygous CFHR1/
CFHR3 deficiency, who had received plasma treatment.
Serum samples obtained before or during plasma treatment
were subjected to Protein-G chromatography. Western blot
analyses of the original samples, the flowthrough, and the
bound fractions (containing IgG and IgG immune com-
plexes) were performed to detect fH and CFHRs (Figure 3).
Serum samples from two healthy individuals, one of them
with homozygous CFHR1/CFHR3 deficiency, were used as
controls; the analysis of these control samples revealed
unspecific binding of factor H-like protein 1 to the column
(Figure 3a). Both free and IgG-bound fH were present in the
two samples from patient H108, although in different
proportions (Figure 3b). Interestingly, when the patient was
under plasma exchange therapy, a significant amount of the
exogenous CFHR1 was IgG-bound, although free fH was still
available. Similar results were observed upon analysis of the
sample from patient H154 obtained during plasma exchange
(Figure 3c). Here, a high proportion of fH appeared in the
flowthrough (suggesting that the autoantibodies were not in
excess), but all exogenous CFHR1 was IgG-bound. These data
suggest a competition between fH and CFHR1 for the
autoantibodies in vivo. To directly assay if such a competition
occurs, a plasma sample from patient H108 obtained before
plasma treatment was incubated with increasing amounts of
recombinant CFHR1, and the levels of free and IgG-bound
fH were estimated by western blot upon Protein-G
chromatography (Figure 3d). CFHR1 reduced the bound/
free fH ratio in a dose-dependent manner, and some CFHR1
appeared IgG-bound at physiological concentrations. In
another set of experiments, the amount of free fH upon
addition of CFHR1 was determined by enzyme-linked
immunosorbent assay, with similar results (Supplementary
Figure S3 online).
CFHR1 neutralizes anti-fH autoantibodies and thus
reverts fH dysfunction
Plasma from aHUS patients with mutations in SCR20 of
fH,16 or with anti-fH autoantibodies,10,15 cause complement-
mediated lysis of sheep erythrocytes (SRBC). As SCR20 of fH
and SCR5 of CFHR1 differ only in two amino acids, and both
proteins are recognized by most anti-fH autoantibodies
(Figure 1), we studied whether CFHR1 protects SRBC from
autoantibody-induced or mutation-induced hemolysis.
Similar to fH, recombinant CFHR1 rescued SRBC from
hemolysis when added to autoantibody-positive aHUS
plasma (Figure 4a), whereas the recombinant SCR15–20
fragment of fH had no protective effect. The lysis-inhibitory
effect of fH and CFHR1 was dose-dependent, although a
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Figure 2 | In vivo generation of CFHR1/autoantibody immune
complexes. IgG fractions isolated from plasma of four
autoantibody-positive aHUS patients and from two healthy
individuals were analyzed for the presence of fH and CFHR
proteins by western blot using an fH antiserum. Patient P6 had
normal levels of CFHR1 and CFHR3, whereas the other patients
presented homozygous CFHR1/CFHR3 deficiency. fH was
detected in the IgG fractions from the four patients (lanes 1–4),
but not from the healthy individuals (lanes 5–6). The two
glycosylated forms of CFHR1 (CFHR1a and CFHR1b) were
identified in patient P6 (lane 1), who had normal levels of CFHR1,
and in a sample from patient P20 obtained after plasma therapy
(lane 4). CFHR1 was not detected in the samples from patients P3
and P10, who were CFHR1 deficient (lanes 2–3), and in the control
IgG samples (lanes 5–6). Ab, antibody; aHUS, atypical hemolytic
uremic syndrome; CFHR, complement factor H-related protein; fH,
factor H; IgG, immunoglobulin G.
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higher concentration of exogenous CFHR1 was required to
achieve the same degree of inhibition as with fH (Figure 4b).
This is likely attributed to the potent complement regulatory
activities of fH in plasma and on cells, because the affinity of
autoantibodies to fH and CFHR1 was similar. The effect of
CFHR1 was also analyzed when the abnormal hemolysis
occurred due to a mutation (W1183L) in SCR20 of fH
(Figure 4c). In this assay, a minor inhibitory effect of CFHR1
was observed at high concentrations, but this effect was very
similar to that of recombinant CFHR4B used as control, and
thus most probably nonspecific. These results indicate that
CFHR1 inhibits the autoantibody-induced lysis by binding to
the autoantibodies, but not by a direct inhibitory effect on
complement-mediated lysis. To elaborate on this finding, we
analyzed whether CFHR1 can inhibit the hemolysis induced
in normal human plasma by two monoclonal anti-fH
antibodies, mAb C18 and mAb OX24, recognizing different
SCR domains.
SRBC lysis is caused in normal human plasma by mAb
C18, which recognizes SCR20 of fH and mimics the effects of
the anti-fH autoantibodies.15 A dose-dependent inhibition of
this lysis was achieved when fH was added, and the same
effect was observed with fH SCR15-20 and with CFHR1
(Figure 5a). Lysis of SRBC in normal human plasma can also
be induced by the mAb OX24, which binds to SCR5 of fH,17
and likely interferes with the regulatory activities of the
adjacent SCR1-4. Addition of fH abrogated the OX24-induced
lysis (Figure 5b), but the effects of exogenous SCR15–20 or
CFHR1 were strikingly different. Increased lysis was observed
in the presence of SCR15–20, which is not recognized by mAb
OX24 but which competes with fH for cell binding
(Supplementary Figure S4 online). On the other hand, the
minor effect of CFHR1 was similar to the one observed in the
mutation-associated hemolysis assay (Figure 5c).
Altogether these data indicate that CFHR1 specifically
reverts the fH dysfunction caused by autoantibodies against
SCR20.
DISCUSSION
In this report we identify CFHR1 as a second autoantigen of
anti-fH autoantibodies in aHUS. We have characterized anti-
fH autoantibodies from a total of 24 German and Spanish
aHUS patients. All autoantibodies recognized SCR20 of fH.
This domain differs only in two amino acids from the
homologous SCR5 domain in CFHR1; in line with this, 21 of
24 anti-fH IgG and 3 of 3 anti-fH IgA bound CFHR1 in vitro.
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Figure 3 |Characterization of IgG-immune complexes before and during plasma treatment. Western blot analysis of serum samples
from two control individuals (Control 1 and Control 2) and two aHUS patients (H108 and H154) on Hi-Trap Protein-G chromatography.
The original (OR), flow-through (FT), and bound fractions (B) were analyzed for the presence of fH and CFHR proteins using rabbit polyclonal
antibodies (also recognizing factor H-like protein 1 (CFHL1), an alternative splicing product of the CFH gene). The two aHUS patients and the
control individual 1 have homozygous deficiency of CFHR1 and CFHR3 (DefR1R3), while the control individual 2 has normal expression of
these two proteins. (a) Analysis of the control samples revealed unspecific binding of CFHL1 to the Protein-G column, but there was no
binding of fH or CFHR1. (b) In the untreated sample from patient H108 both free and IgG-bound fH were detected. In the sample obtained
during plasma exchange treatment, most of fH and of the exogenous CFHR1 appeared IgG-bound, indicating the presence of fH- and
CFHR1-immune complexes. (c) In patient H154, all the exogenous CFHR1 was detected in the IgG fraction, while a great proportion of
fH was still autoantibody-free. CFHR3, CFHR4A, and CFHR5 were not detected in the IgG fractions obtained from controls or patients
(not shown). (d) A plasma sample from patient H108 was incubated with increasing concentrations (0–1 mmol/l) of recombinant CFHR1
at room temperature for 1 h, submitted to Hi-Trap Protein-G chromatography and analyzed by western blot. The ratio of free fH (FT lanes)/
IgG-bound fH (B lanes) band intensity increases with the CFHR1 concentration, demonstrating a competition between fH and CFHR1
for autoantibody binding. aHUS, atypical hemolytic uremic syndrome; CFHR, complement factor H-related protein; fH, factor H; IgG,
immunoglobulin G.
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These results agree with and validate similar findings
reported for the Newcastle cohort, where autoantibodies
from 7 out of 12 aHUS patients recognized SCR19-20 of fH,
and those antibodies also bound to the homologous SCR4-5
of CFHR1.12
Most of the 24 autoantibody-positive aHUS patients
studied here had homozygous CFHR1 deficiency. None-
theless, anti-fH autoantibodies can also be found in patients
expressing CFHR1 (Table 1).12,14 We observed that auto-
antibodies from one of the three CFHR1-positive patients
showed crossreactivity with recombinant CFHR1 and,
importantly, that this interaction occurred in vivo (Figure 2).
CFHR1/IgG immune complexes were also formed in CFHR1-
deficient patients undergoing plasma exchange therapy, even
when free fH was still available for antibody binding
(Figure 3). In this context, we considered it relevant to
analyze the functional consequences of the CFHR1 cross-
reactivity of the anti-fH autoantibodies.
fH is a major fluid-phase complement regulator that
also protects autologous cells from complement-mediated
70
60
50
40
30
20
10
0
70
60
50
40
30
20
10
0
50
40
30
20
10
0
0 0.2 0.4 0.6 0.8 1
Buffer CFHR1 SCR15–20 Factor H
*
*
HSA
0 0.2 0.4 0.6 0.8 1
Inhibitor (μM)
Inhibitor (μM)
Ly
sis
 (%
)
Ly
sis
 (%
)
Factor H
CFHR1
Factor H
CFHR1
CFHR4B
Ly
sis
 (%
)
b
c
a
Figure 4 |CFHR1 reverts the anomalous lysis caused by anti-fH
autoantibodies but not by an fH mutation. (a) An anti-fH
autoantibody-positive plasma (P16) causes enhanced lysis of SRBC
(buffer). The effect of fH, recombinant fH fragment SCR15–20,
recombinant CFHR1, and human serum albumin (HSA) on the
hemolysis was tested. Proteins were added at 1 mmol/l
concentration, and hemoglobin release was measured in the
supernatant after 30 min incubation at 371C. Data represent
meanþ s.d. from three independent experiments. Asterisks
indicate significant differences (Po0.01; Student’s t-test) from the
control, HSA-treated plasma. (b) fH and recombinant CFHR1
inhibited the anomalous SRBC lysis observed in 10% plasma from
the autoantibody-positive patient H154. Complete inhibition was
achieved at 1 mmol/l CFHR1. (c) The anomalous lysis observed in
the plasma from an aHUS patient with the mutation W1183 L in
SCR20 of fH is fully inhibited by addition of fH, as previously
described.16 By contrast, the effect of recombinant CFHR1 was
similar to that of recombinant CFHR4B, included as a control, and
therefore considered to be unspecific. The experiments in panels
b and c were performed in parallel twice with similar results.
CFHR, complement factor H-related protein; fH, factor H.
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Figure 5 |CFHR1 reverts the lysis caused by mAb C18 but not
by mAb OX24. (a) Addition of 1.5 mg mAb C18, which recognizes
SCR20 of fH and SCR5 of CFHR1, to 10% normal human plasma
induces SRBC lysis. This lysis was inhibited by exogenous fH,
CFHR1, and the fH SCR15–20 fragment, added in the indicated
concentrations. (b) The mAb OX24, which recognizes fH but not
SCR15-20 or CFHR1, also induces SRBC lysis in normal human
plasma. Accordingly, the OX24-induced lysis is inhibited by
exogenous fH, but not by SCR15–20 or by CFHR1. The
experiments in panels a and b were performed in parallel twice
with similar results. CFHR, complement factor H-related protein;
fH, factor H; mAb, monoclonal antibody.
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damage.7,8 The C terminus of fH, particularly SCR20, is
critical for its cell-protective function, as it interacts with
polyanionic molecules on cell surfaces and with C3b
deposited during complement activation.7–9,18 Mutations in
the fH C terminus or autoantibodies against this region cause
reduced fH binding to cells, and thus a reduced protection
from complement-mediated damage, which can be measured
in vitro with a hemolysis assay using SRBC.10,15,16,19,20 We
used this kind of assay to compare the effect of exogenous
fH and CFHR1, and found that CFHR1 could revert the
anomalous lysis caused by plasma samples of autoanti-
body-positive aHUS patients, but not the lysis due to
a mutation in fH SCR20. A similar inhibitory effect of
CFHR1 was observed when SRBC lysis was induced in
normal human plasma by the mAb C18, which recognizes the
C-terminal domains of fH and CFHR1, but CFHR1 could
not inhibit the lysis induced by the mAb OX24, which binds
to the N terminus of fH. Therefore, our results indicate that
CFHR1 can revert the fH dysfunction caused by anti-fH
autoantibodies. Thus, CFHR1 derived from exogenous
plasma during therapy could have a beneficial effect by
neutralizing the autoantibodies. This also raises the possibi-
lity of using recombinant CFHR1 as a decoy for the
antibodies.
CFHR1 has been shown to inhibit the terminal pathway
when applied at high concentrations.21 Nonetheless, in our
assays this effect could be excluded because CFHR1 inhibited
the autoantibody-mediated lysis already at lower concentra-
tions. The minor effect of CFHR1 on mutation- or mAb
OX24-induced lysis was considered unspecific, as CFHR4B
had the same effect. In addition, no enhanced hemolysis was
observed in CFHR1-deficient normal human plasma15 or in
plasma from eight aHUS patients lacking both CFHR1 and
anti-fH autoantibodies (data not shown).
CFHR1 shares ligand-binding capacities with fH due to
their very similar C-terminal domains. Thus, CFHR1 binds
to C3b and to endothelial cells21,22 (Supplementary Figure S1
online) and has been shown to inhibit the binding and
regulatory activity of fH on a bacterial ligand.23 Therefore, it
has been suggested that CFHR1 competes with fH for ligand
and cell binding.6 Interaction of fH with host cells, however,
involves the binding to a complex of cell surface polyanions
and deposited C3b,24 and the affinity of CFHR1 for C3b is
lower than that of fH.21 Indeed, the two amino acid
differences between SCR20 of fH and SCR5 of CFHR1 have
been identified as aHUS-associated fH mutations that cause
reduced C3b binding,25 and such CFHR1-like C terminus is
also present in the fH::CFHR1 hybrid protein.4 While a wild-
type recombinant SCR19–20 fragment competes with fH for
cell binding and thus causes SRBC lysis when added to
human plasma, a mutant SCR19–20 fragment with the
S1191L and V1197A exchanges, corresponding to L290 and
A296 of CFHR1, had an impaired ability to compete with fH
and thus to cause hemolysis.24 In line with these findings,
recombinant CFHR1 did not cause SRBC lysis when added to
normal plasma at the concentrations tested (up to 4mM
CFHR1, corresponding to B150 mg/ml protein). In contrast
to this, the fH SCR15–20 fragment enhanced lysis when
added at high concentrations due to competition with fH
(Supplementary Figure S4 online), and it did not protect
SRBC from antibody-induced hemolysis (Figure 4), thus
rendering this fragment inappropriate for use as an inhibitor
of the autoantibodies.
Although there is no consensus treatment for aHUS
patients with anti-fH autoantibodies, to apply plasma
exchanges combined with immunosuppressive therapy is a
logical choice.15,26–29 The patients differ, however, in their
response and tolerance to these treatments.15 A supplemen-
tation with purified fH could help to restore the complement
regulation impaired by the autoantibodies. However, purified
fH as a therapeutic agent is currently not available; on
the other hand, while it could supply fully active free fH, it
does not solve the problem of continuous autoantibody
production in the patients. There is also the inherent risk of
transmitting infectious agents such as viruses or prion
proteins. Thus, a combination of immunosuppression to
inhibit autoantibody production, and supplementation with
recombinant fH, and/or with CFHR1 that will act as an
autoantibody decoy, could be considered (Supplementary
Figure S5 online). It would be easier to generate recombinant
CFHR1 (5 SCR domains) than fH (20 SCR domains). The
risk of immunization with recombinant CFHR1 is unlikely
to be higher than in the case of plasma exchanges, when
exogenous CFHR1 is also provided and CFHR1-immune
complexes are generated. Furthermore, CFHR1 is almost
a perfect hybrid of SCR1–2 of CFHR2 and SCR18–20 of fH,
two closely related proteins present in the patients’ plasma.
Clinical trials will be necessary to establish the efficacy of
these and other treatments (including the administration
of fresh frozen plasma, plasmapheresis, plasma exchanges,
and immunosuppressive treatments), as well as the effect
of complement inhibitors (e.g., anti-C5 antibody) that could
be beneficial in the acute phase of the disease, when systemic
complement activation is often observed.
In conclusion, our results show that most anti-fH
autoantibodies in aHUS patients crossreact with CFHR1
and can recognize this protein when administered exogen-
ously during plasma treatments. These results indicate that
plasma exchanges have multiple beneficial effects: in addition
to removing autoantibodies and providing free fH, the
exogenous CFHR1 prevents the remaining autoantibodies
from fH binding. Thus, to include exogenous CFHR1 could
be helpful in the treatment of autoimmune aHUS. Prospec-
tive clinical trials will help identify the best therapeutic
option for each patient.
We also report for the first time the presence of anti-fH
antibodies of the IgA isotype in aHUS patients. This finding
is of potential relevance, because IgAs have been associated
with a poor prognosis in thrombotic microangiopathy and in
nephropathies.30,31 Whether the IgA isotype in autoimmune
aHUS is associated with a different disease evolution needs to
be addressed in larger patient cohorts.
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MATERIALS AND METHODS
Blood samples
Serum or ethylenediaminetetraacetate–plasma samples were
obtained from 24 pediatric aHUS patients, who had been previously
detected to have anti-fH IgG, and from several control individuals.
Overall, 20 patients (P1–P20) were from a German aHUS
cohort10,11,15 and 4 patients (H108, H151, H154, and H177) were
of Spanish origin.13 The studies were performed with approval of
the Research Ethics Committees of the Medical Faculty of the
Friedrich Schiller University and of the University Hospital ‘La Paz’,
in accordance with the Declaration of Helsinki Principles. Written
informed consent was obtained from the patients’ relatives.
Microtiter plate assays
Autoantibody binding to fH and to recombinant CFHR proteins was
measured by enzyme-linked immunosorbent assay using MaxiSorp
plastic plates (Nunc, Wiesbaden, Germany).10 Purified fH was
purchased from Merck (Schwalbach, Germany). Recombinant
CFHR1, CFHR4A, and CFHR4B were expressed in the baculo-
virus-insect cell expression system.32 Recombinant CFHR1, CFHR3,
and fH SCR15–20 fragment, as well as antibodies and plasma
samples, were kindly provided by Peter F. Zipfel (Hans Kno¨ll
Institute, Jena). Peroxidase-conjugated anti-human IgA was from
Sigma-Aldrich (Taufkirchen, Germany). The mAb 90X and A229
were obtained from Quidel (TECOmedical; Bu¨nde, Germany).
Inhibition experiments were performed with the mAb C18
(Enzo Life Sciences, Lo¨rrach, Germany), which recognizes fH
SCR20.9 The wells were coated with fH or CFHR1, and the plasma
samples were added in the presence or absence of mAb C18.
Hi-Trap Protein-G chromatography
Ethylenediaminetetraacetate–plasma samples from patients or con-
trol individuals were dialyzed against 20mmol/l sodium phosphate,
pH 7.0, and loaded onto 1-ml Hi-Trap Protein-G columns (GE
Healthcare, Uppsala, Sweden). Chromatography was performed
according to the manufacturer’s instructions using an A¨KTA-Prime
system (GE Healthcare). IgG and IgG-immune complexes were
eluted with 0.1 M Glycine–HCl, pH 2.7, and immediately neutralized
with appropriate volumes of 1.5 M Tris-HCl, pH 8.8. After dialysis
against phosphate-buffered saline, IgG concentration was deter-
mined by reading A280 (E
0.1%¼ 1.35), and the samples were stored
at 201C.
The flow-through fraction obtained from a control sample
(containing all plasma proteins except for IgG) was further
processed to obtain a preparation of plasma-derived fH and CFHR
proteins by affinity chromatography on Heparin-Sepharose as
described.13 Briefly, fH and CFHR proteins were retained in the
Heparin-Sepharose column at low ionic strength (50mmol/l NaCl)
and further eluted at 500mmol/l NaCl. This protein preparation was
free from IgG and albumin, among other plasma proteins.
Western blot assays
Western blot analyses of fH and CFHR proteins in plasma samples,
and in the flow-through and IgG fractions obtained after Hi-Trap
Protein-G chromatography, were performed using polyclonal
antibodies as described.13
Western blots to determine whether the IgG fractions of
aHUS patients with anti-fH autoantibodies recognize plasma-
derived fH and CFHRs were also performed. A volume of 25 mg of
the protein preparation was separated by 10% sodium dodecyl
sulfatc-polyacrylamide gel electrophoresis and transferred onto
nitrocellulose membranes. Purified IgG from patients H154 and
H177, or from a control individual, were added as primary
antibodies, and horseradish peroxidase-conjugated goat anti-human
IgG (Biosource, Invitrogen, Carlsbad, CA) as secondary antibody.
The membranes were developed using a chemiluminescent substrate
(ECL Advance kit; GE Healthcare) as described.13
Hemolysis assays
The ability of purified fH, recombinant CFHR1, and fH SCR15–20
to inhibit lysis of sheep erythrocytes (SRBC) was compared using
three kinds of assays: (1) lysis induced by anti-fH autoantibodies.
fH, CFHR1, or SCR15-20 were added to 20% autoantibody-positive
plasma for 5min at 201C, then incubated with SRBC for 30min at
371C as described.10 (2) Lysis induced by mAbs. fH, CFHR1, or
SCR15–20 were added to 10% normal human plasma in the presence
of the mAb OX24 (binding to SCR5 of fH)17 or mAb C18, and then
incubated with SRBC. (3) Lysis induced by an fH mutation. fH,
CFHR1, or CFHR4B were added to 10% plasma from an aHUS
patient carrying the mutation W1183L in fH SCR20,16 and then
incubated with SRBC. Hemoglobin release was determined by
reading the absorbance at 414 nm.
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